Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...
Streetwise Reports | January 3, 2020 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |

SunPower (SPWRA): Retreating into familiar territory

Last week, SunPower Corporation ( NASDAQ: SPWRA , Stock Forum ) updated its 2011 guidance, predicting that ex-items earnings per share would range between $1.75 and $2.05. Revenue for the upcoming fiscal year is predicted to arrive between $2.65 billion and $2.85 billion....
Andrea Kramer | October 28, 2012 |

Cummins (CMI): Bullish bandwagon far from crowded

Engine issue Cummins Inc. ( NYSE: CMI , Stock Forum ) has been a broad-market standout, to say the least, besting its fellow S&P 500 Index (SPX) comrades with a gain of roughly 140% in 2010. What’s more, the equity has outperformed the SPX by almost 12% du...
Andrea Kramer | October 28, 2012 |

Chesapeake Energy (CHK): Can its stock continue to make new highs?

Chesapeake Energy Corp. ( NYSE: CHK , Stock Forum ) has embarked on a quest for new multi-year highs this week, after last night announcing a deal with CNOOC Ltd. ( NYSE: CEO , Stock Forum ). More specifically, the China-based firm said it will buy into several of Chesape...
Andrea Kramer | October 28, 2012 |

Deadly Mine Collapse in the DRC to Have Repercussions

The potential effects of the event on the copper market and the project's major joint venture partner are outlined in a BMO Capital Markets report. In a June 27 research note, BMO Capital Markets analyst Ed Sterck wrote that the fatal mine collapse from ...
Streetwise Reports | July 2, 2019 |

Global Gold Miner Now Rated Outperform on Potential of Nevada JV

The reasons for the upgrade are provided in a BMO Capital Markets report. In a July 3 research note, analyst Andrew Kaip reported that BMO Capital Markets upgraded Barrick Gold Corp. (ABX:TSX; GOLD:NYSE) to an Outperform rating on the potential of its ...
Streetwise Reports | July 12, 2019 |

Rating, Target Upgraded on Gold Mining Major Undergoing a Turnaround

The reasons to be optimistic about this company are covered in a BMO Capital Markets report. In a Sept. 11 research note, analyst Andrew Kaip reported that his firm BMO Capital Markets upgraded its rating to Outperform and raised its target price to $50 per share from...
Streetwise Reports | September 18, 2019 |

'Strong Finish' to 2019 for Miner, 'Dividend Beat Expectation'

Last year's performance by Glencore International is summarized in a BMO Capital Markets report. In a Feb. 18 research note, BMO Capital Markets analyst Edward Sterck reported that Glencore International Plc's (GLEN:LSE) H2/19 results were "better than exp...
Streetwise Reports | February 28, 2020 |
1 2 3 4 5 6 7 8 9